Aptar

The Entrepreneur of the Year program honors leaders who are reshaping industries and creating lasting impact. Winners are selected by an independent panel based on entrepreneurial spirit, strategic vision and sustained value creation. For Aptar, this achievement reflects the strength of our global team and our shared commitment to delivering innovative solutions that improve everyday life.

The recognition highlights his leadership, strategic vision and impact on Aptar’s continued growth and innovation. Since 2017 under Stephan’s leadership, adjusted EBITDA margins expanded from approximately 19% for the yearend 2017 to approximately 22% for the yearend 2025, adjusted earnings per share grew 67% with the majority of capital allocated to Pharma, helping establish it as Aptar’s largest and most profitable segment.

Aptar was named a CDP Supplier Engagement Leader, for the sixth consecutive year. This assessment, based on information reported within the 2025 CDP reporting cycle, highlights companies that are engaging their suppliers on climate change and supporting efforts to address emissions throughout the value chain. By evaluating supplier engagement and recognizing best practices, CDP aims to accelerate global action on supply chain emissions and the transition towards a more sustainable economy.

Aptar Pharma is looking forward to exhibiting at CPHI Milan 2026, taking place at Fiera Milano, Italy October 6-8, 2026. Meet our team in hall 11 - booth 11A43 to learn more about how Aptar Pharma can support your drug delivery project through our comprehensive portfolio of solutions and services, from formulation to patient. A limited number of free access passes are available for CPHI Milan. Register now to secure your complimentary ticket, offered on a first-come, first-served basis.

Aptar is proud to announce that its advanced packaging solution, Swift Me™, has been honored with the ‘Innovative Technology Award’ at the 8th iSEE Awards. Hosted by Foodaily, a leading authority in food innovation, the iSEE Award is a premier international accolade recognized for its rigorous ‘International Standard + Independent Authority + Non-Commercial’ evaluation process. The organization aims to recognize benchmark cases that drive industry innovation and enhance user experience.

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the publication of three new international patent applications focused on enabling inhaled and nasal delivery of GLP‑1‑based therapies. The applications arise from an internal strategic R&D program intended to expand Aptar Pharma’s capabilities in biologics delivery and strengthen its intellectual property position in high-growth therapeutic areas.

Crystal Lake, Illinois, May 27, 2026 -- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it will present at two upcoming investor conferences: Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 12:45 p.m. Eastern Standard Time.

GLP-1 formulations are not standard injectables Liraglutide, semaglutide, tirzepatide and the molecules following them present chemical sensitivity profiles that materially affect their interaction with primary packaging. Compared with conventional small‑molecule injectables, the impact of: extractables from elastomeric components silicone oil particles from plunger coatings surface interactions at the stopper–drug interface may be amplified.

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced continued progress on its awarded research contract with the U.S. Food and Drug Administration (FDA) focused on advancing scientific understanding related to the transition of metered‑dose inhalers (MDIs) toward next-generation propellants (NGPs).

Aptar today highlighted how its patented, high performance airless dispensing innovation is enabling prestige beauty brands to advance sustainability without compromising performance or luxury. Through a long‑standing partnership with Clarins, Aptar developed a custom, reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, designed to enhance formula protection, dispensing precision and consumer experience.